Given the current lack of evidence linking rilonacept to pulmonary valve function changes, it seems prudent to recommend that patients with significant pre-existing pulmonary valve regurgitation or pulmonary hypertension should receive a baseline cardiac work-up and infection-risk assessment before starting an IL-1 inhibitor, and those with recurrent pericarditis who develop right-heart failure or elevated pulmonary artery pressure should have pulmonary pressure measured to exclude secondary PVI. The gene discussed is IL1B; the disease is pulmonary arterial hypertension.